FORM 51-102F3 MATERIAL CHANGE REPORT

Item 1 – Name and Address of Company

Hemostemix Inc.
#200, 144 – 4 Avenue SW
Calgary, Alberta T2P 3N4

TSXV: HEM
OTCQB: HMTXF
FSE: 2VF0

Item 2 – Date of Material Change

June 17, 2026

Item 3 – News Release

A news release describing the material change was disseminated on June 17, 2026 through approved news dissemination services and filed on SEDAR+.

Item 4 – Summary of Material Change

Hemostemix Inc. announced:

(a) a non-brokered private placement of up to $1,000,000 through the issuance of up to 20,000,000 units at a price of $0.05 per unit, each unit consisting of one common share and one-half common share purchase warrant; and

(b) the filing on SEDAR+ of restated unaudited condensed interim financial statements and corresponding management discussion and analysis for the nine-month period ended September 30, 2025, following the identification of a material accounting misstatement relating to the accounting treatment of the Company's Therapeutic Convertible Debentures.

Item 5 – Full Description of Material Change

On June 17, 2026, Hemostemix Inc. announced a non-brokered private placement of up to $1,000,000. The financing consists of units priced at $0.05 per unit. Each unit consists of one common share and one-half warrant, with each whole warrant exercisable at $0.12 per common share for a period of 24 months from closing, subject to acceleration if the weighted average trading price of the Company's common shares equals or exceeds $0.15 for ten consecutive trading days following the expiry of the statutory hold period.

The proceeds of the financing are intended to support commercialization activities, physician education, patient acquisition, manufacturing readiness, regulatory activities in The Bahamas, and general working capital.

In addition, during preparation of the audited financial statements for the year ended December 31, 2025, management, in consultation with the Company's auditors and Audit Committee, determined that the Therapeutic Convertible Debentures issued on July 14, 2025 should have been accounted for as a single financial liability measured at fair value through profit or loss under IFRS 9.

As a result, the Company's previously filed unaudited condensed interim financial statements and MD&A for the nine-month period ended September 30, 2025 were restated and refiled on SEDAR+ on June 17, 2026. The Company advised that the previously filed Q3 2025 interim financial statements and MD&A should no longer be relied upon.

The restatement primarily affected the valuation methodology applied to the Therapeutic Convertible Debentures, foreign exchange adjustments, finance expense, professional fees, and associated liability measurements. The Company reported that the restatement does not affect cash, operating activities, or previously disclosed business strategy.

Item 6 – Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7 – Omitted Information

No information has been omitted on the basis that it is confidential.

Item 8 – Executive Officer

Thomas Smeenk
President and Chief Executive Officer
Hemostemix Inc.
905-580-4170

Item 9 – Date of Report: June 19, 2026